Product Description
CD70-targeting UCAR-T cells. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT06383507?term=CHT-101&draw=2&rank=1)
Mechanisms of Action: CAR-T,CD70
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for CHT-101](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Cervical Cancer|Head and Neck Cancer|Nasopharyngeal Cancer|Ovarian Cancer|Renal Cell Carcinoma|Squamous Cell Carcinoma|Uterine Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CHT101 | P1 |
Not yet recruiting |
Renal Cell Carcinoma|Cervical Cancer|Squamous Cell Carcinoma|Uterine Cancer|Nasopharyngeal Cancer|Head and Neck Cancer|Ovarian Cancer |
2027-04-21 |